Menu Search
Equities

Pharvaris NV

  • Add to watchlist
  • Add to portfolio
  • Add an alert
9EN:FRA

Pharvaris NV

Actions
  • Price (EUR)23.00
  • Today's Change0.00 / 0.00%
  • Shares traded114.00
  • 1 Year change+37.72%
  • Beta-2.7784
Data delayed at least 15 minutes, as of Feb 10 2026 20:55 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.

  • Revenue in USD (TTM)0.00
  • Net income in USD-195.04m
  • Incorporated2015
  • Employees108.00
  • Location
    Pharvaris NVEmmy Noetherweg 2LEIDEN 2333 BKNetherlandsNLD
  • Phone+31 712036410
  • Websitehttps://pharvaris.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.